Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.78 |
| ▸ | BLM | P54132 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611352 | 1.00 | ACHE (0.78) | ACHEBLMTSHRNPSR1NR1I2 | |
| SCHEMBL7428417 | 0.88 | ACHE (1.00) | ACHEBLMTSHRNPSR1NR1I2 | |
| SCHEMBL7427390 | 0.88 | ACHE (1.00) | ACHEBLMTSHRNPSR1NR1I2 | |
| SCHEMBL5278538 | 0.86 | BLM (0.65) | ACHEBLMTSHRNPSR1NR1I2 | |
| SCHEMBL10042341 | 0.85 | ACHE (0.78) | ACHEBLMTSHRNPSR1NR1I2 | |
| Acetic Acid SCHEMBL7438982 | 0.85 | ACHE (0.94) | ACHEBLMTSHRNPSR1NR1I2 | |
| SCHEMBL3653388 | 0.83 | BLM (0.69) | ACHEBLMTSHRNPSR1TDP1 | |
| SCHEMBL7901872 | 0.82 | TSHR (0.68) | ACHEBLMTSHRNPSR1NFKB1 | |
| Water SCHEMBL11670111 | 0.81 | BLM (0.67) | ACHEBLMTSHRNPSR1TDP1 | |
| SCHEMBL140947 | 0.81 | TSHR (1.00) | ACHEBLMTSHRNPSR1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020013312-A1 | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-01-31 | — | — | US | claimed |
| US-20090221552-A1 | Methods for the Treatment of ADHD and Related Disorders | THE MCLEAN HOSPITAL CORPORATION (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090203607-A1 | Method And Compositions For Simultaneously Regulating Memory And Mood | BRC OPERATIONS PTY LIMITED (AU) | 2009-08-13 | — | — | US | disclosed |
| WO-2008019431-A1 | METHOD AND COMPOSITIONS FOR SIMULTANEOUSLY REGULATING MEMORY AND MOOD | BRC OPERATIONS PTY LIMITED (AU) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007100777-A2 | METHODS FOR THE TREATMENT OF ADHD AND RELATED DISORDERS | THE MCLEAN HOSPITAL CORPORATION (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | US | disclosed |
| WO-2004103283-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CENTRAL NERVOUS SYSTEM STIMULANT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-6403645-B2 | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-06-11 | — | — | US | disclosed |
| US-6403645-B2 | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-06-11 | — | — | US | disclosed |
| US-20020013312-A1 | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-01-31 | — | — | US | disclosed |
| US-20020013312-A1 | Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | GAP43, PTGS2, CNR2 | ACHE 4/4885BLM 1628/4885TSHR 3373/4885 |
| US-20090221552-A1 | Methods for the Treatment of ADHD and Related Disorders | SLC6A3, SLC6A2, SLC6A4 | ACHE 159/4885BLM 3551/4885TSHR 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.